Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease

BACKGROUND: Treatment of infantile-onset inflammatory bowel disease (IO-IBD) is often challenging due to its aggressive disease course and failure of standard therapies with a need for biologics. Secondary loss of response is frequently caused by the production of anti-drug antibodies, a well-known...

Descripción completa

Detalles Bibliográficos
Autores principales: Ancona, Silvana, Signa, Sara, Longo, Chiara, Cangemi, Giuliana, Carfora, Roberta, Drago, Enrico, La Rosa, Alessandro, Crocco, Marco, Chiaro, Andrea, Gandullia, Paolo, Arrigo, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600799/
https://www.ncbi.nlm.nih.gov/pubmed/37900586
http://dx.doi.org/10.3748/wjg.v29.i38.5428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600799/
https://www.ncbi.nlm.nih.gov/pubmed/37900586
http://dx.doi.org/10.3748/wjg.v29.i38.5428

Ejemplares similares